[144] FEDERATED HERMES, INC. SEC Filing
Rhea-AI Filing Summary
FHI reported a planned sale of common stock under Rule 144 by insider Saker Anwar Nusseibeh. The notice covers the proposed sale of 4,461 common shares through Morgan Stanley Smith Barney LLC on the NYSE, with an indicated aggregate market value of $213,447.25. The filing notes that these shares come from restricted stock that vested under a registered plan on the same date, in exchange for services rendered.
The form also discloses that during the prior three months, the same seller disposed of 15,000 common shares for gross proceeds of $728,154.00. By signing the notice, the seller represents that they are not aware of any material adverse, non‑public information about the issuer’s current or prospective operations.
Positive
- None.
Negative
- None.
FAQ
What does the FHI Form 144 filing disclose about insider share sales?
The Form 144 for FHI discloses that insider Saker Anwar Nusseibeh plans to sell 4,461 common shares through Morgan Stanley Smith Barney LLC on the NYSE under Rule 144.
How many FHI shares are covered by the new Rule 144 notice and what is their value?
The notice covers 4,461 common shares of FHI with an indicated aggregate market value of $213,447.25 as listed in the filing.
How were the FHI shares in this Form 144 acquired by the insider?
The 4,461 common shares were acquired as restricted stock vesting under a registered plan from the issuer, in exchange for services rendered on the stated acquisition date.
What prior FHI share sales by this insider are disclosed in the Form 144?
The filing states that over the past three months, Saker Anwar Nusseibeh sold 15,000 common shares of FHI, generating gross proceeds of $728,154.00.
How many FHI shares are reported as outstanding in the Form 144?
The securities information section reports 77,537,867 common shares outstanding for FHI at the time referenced in the filing.
What representation does the insider make about non-public information in the FHI Form 144?
By signing, the seller represents that they do not know any material adverse information about the issuer’s current or prospective operations that has not been publicly disclosed.